

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT 95 TYPES OF PRODUCTS INCLUDED IN NATIONAL ESSENTIAL MEDICINES LIST (2026 EDITION)

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that a total of 95 types (with 141 specifications) of products of the Group have been included in the National Essential Medicines List (2026 Edition) of China (the “List”), including the newly added 32 types (with 37 specifications), namely Glucose & Sodium Chloride Injection, Levofloxacin Lactate & Sodium Chloride Injection, Levofloxacin & Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Gliclazide Tablets, Clear Heat & Detox Oral Liquid, Potassium Chloride Injection, Mecobalamin Injection, Ambroxol Hydrochloride Injection, Bromhexine Hydrochloride Injection, Medium/Long Chain Fat Emulsion Injection, Azithromycin for Injection, Paracetamol Tablets, Azithromycin for Suspension, Ipratropium Bromide Solution for Inhalation, Lurasidone Hydrochloride Tablets, Urapidil Hydrochloride Injection, Citicoline Sodium Injection, Oseltamivir Phosphate for Suspension, Aminophylline Injection, Magnesium Sulfate Injection, Cefuroxime Axetil for Suspension, Ondansetron Hydrochloride Injection, Entacapone Tablets, Isosorbide Dinitrate Injection, Betahistine Mesilate Tablets, Norepinephrine Bitartrate Injection, Levamlodipine Besilate Tablets, Levofloxacin Eye Drops, Propafenone Hydrochloride Injection and Metoclopramide Hydrochloride Injection. The List will become effective on 1 September 2026, which is expected to have a positive impact on the growth and business development of the Group.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 10 July 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.